Health Industry News
New Colombian comms partner strengthening our Global Health Marketing & Communications capabilities
To further strengthen our global network’s health communications expertise, Global Health Marketing & Communications (GHMC) today announced the addition of its newest member, Monodual Libera Ideas, a Colombian-based strategic communications, and consulting firm. GHMC is the world’s largest and most robust network of independent healthcare agencies, for which we – VIVA! Communications – have represented…
Read MoreTick of approval needed for Alzheimer’s disease medication in AUS
There are calls for the Therapeutic Goods Administration (TGA) to greenlight a breakthrough medication with the potential to slow the progression of Alzheimer’s disease. The Federal Drug Administration (FDA) recently approved humanised monoclonal antibody Lecanemab for use in patients with the neurodegenerative disease, in the wake of promising clinical trial outcomes. The medication, marketed as…
Read MoreVIVA! Communications clinches gold & two silvers at Public Relations Institute of Australia Golden Target Awards
Team VIVA! was dressed to impress at the annual PRIA Golden Target Awards (GTAs) held at the Sofitel Darling Harbour, Sydney, last night (Thursday, December 1, 2022). A show-stopping 146 finalists representing 35 categories assembled for Australia’s longest-running, and most prestigious public relations and communications awards that both celebrate, and recognise, individuals, agencies and campaigns demonstrating strategic…
Read MoreVIVA! Communications clinches Best PR Campaign – Awareness and Advocacy with Edwards Lifesciences at the 2022 PRIME Awards
VIVA! Communications marked the 18th annual PRIME Awards in style last night (Thursday, November 10, 2022) together with our much-valued clientele, Edwards Lifesciences and Dr Falk Pharma, and Australian representatives from the pharmaceutical industry, at the Sofitel Wentworth Sydney Hotel. Hosted by comedian, musician and former member of ABC TV’s satirical program, The Chaser,…
Read More
First treatment in 10 years PBS listed for Aussies
living with aggressive stomach & oesophageal cancers
Australians living with types of aggressive stomach or oesophageal cancers can now access immunotherapy on the Pharmaceutical Benefits Scheme (PBS), representing the first treatment advance for many of these patients in a decade. OPDIVO® (nivolumab) in combination with chemotherapy, is now reimbursed as an initial treatment for patients with a type of stomach or oesophageal…
Read More